

**Adult CIRB - Late Phase Emphasis Meeting Agenda**

**October 3, 2024**

---

**I Amendment**

**RTOG-1216**, Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk, Squamous Cell Cancer of the Head and Neck (Version Date 08/29/24)

---

**II Continuing Review**

**A012103**, OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy (Version Date 04/24/24)

---

**III Continuing Review**

**NRG-GY033**, A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor (Version Date 05/01/24)

---

**IV Continuing Review**

**A031702**, A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) (Version Date 04/10/24)

---

**V Continuing Review**

**A071701**, Genomically-Guided Treatment Trial in Brain Metastases (Version Date 01/08/24)

---

## **VI Continuing Review**

**CCTG CE.7**, A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases (Version Date 04/01/22)

---

## **VII Continuing Review**

**NRG-LU005**, Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab (Version Date 07/10/24)

---

## **VIII Continuing Review**

**GOG-0213**, A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (Or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865, IND #113912) followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912) NCT# 00565851 (Version Date 11/16/18)

---

## **IX Continuing Review**

**GOG-0281**, A Randomized Phase II/III Study To Assess The Efficacy of Trametinib (GSK 1120212) In Patients With Recurrent Or Progressive Low-Grade Serous Ovarian Cancer Or Peritoneal Cancer. NCT # NCT02101788 (Version Date 09/19/22)

---

## **X Continuing Review**

**NRG-GY028**, A Phase IB and Randomized Phase II Trial of Megestrol Acetate with or without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer (Version Date 03/26/24)

---

## **XI Continuing Review**

**S2302, Pragmatica - Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Version Date 03/01/24)**

---